Dr. Jack H. Florin, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (1970)
- Years since graduation
- 56
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 441
Licensed in California since 1974, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1970Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license G26561 (first issued 1974; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 441
- Services billed
- 26,238
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 22,700 | 41 |
| Injection, eptinezumab-jjmr, 1 mg | 14,400 | 32 |
| Established patient office or other outpatient visit, 30-39 minutes | 561 | 325 |
| Established patient office or other outpatient visit, 20-29 minutes | 332 | 163 |
| New patient office or other outpatient visit, 45-59 minutes | 151 | 151 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 130 | 42 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 110 | 34 |
| Established patient office or other outpatient visit, 40-54 minutes | 45 | 40 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 32 | 12 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 32 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Fullerton, CA | 153 |
| Memantine Hcl Other prescribers in Fullerton, CA | 121 |
| Gabapentin Other prescribers in Fullerton, CA | 101 |
| Donepezil Hcl Other prescribers in Fullerton, CA | 101 |
| Lamotrigine Other prescribers in Fullerton, CA | 74 |
| Sumatriptan Succinate Other prescribers in Fullerton, CA | 69 |
| Pregabalin Other prescribers in Fullerton, CA | 66 |
| Rizatriptan (rizatriptan benzoate) Other prescribers in Fullerton, CA | 63 |
| Clonazepam Other prescribers in Fullerton, CA | 51 |
| Baclofen Other prescribers in Fullerton, CA | 49 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $820 in total to this clinician.
| Lilly USA, LLC | $700 |
|---|---|
| Novartis Pharmaceuticals Corporation | $64.31 |
| Axsome Therapeutics, Inc. | $29.77 |
| Telix Pharmaceuticals | $25.43 |
| Compensation for services other than consulting (speaking, faculty) | $700 |
|---|---|
| Food and Beverage | $120 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $700 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 5 companies. The companies reported $3,125,094 in research payments for these studies, mostly to the institutions running them.
- An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
Novartis Pharmaceuticals Corporation - A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension …
Novartis Pharmaceuticals Corporation - A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation - A phase iii study to evaluate the efficacy and safety of fenebrutinib in adults with progressive ms
Genentech, Inc. - Study to Evaluate SAGE-324 in Participants With Essential Tremors
Sage Therapeutics, LLC - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimer…
E.r. Squibb & Sons, L.l.c. - A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase
Novartis Pharmaceuticals Corporation - A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
Sage Therapeutics, LLC - A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Novartis Pharmaceuticals Corporation - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047457
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.